vs
GLAUKOS Corp（GKOS）与3M（MMM）财务数据对比。点击上方公司名可切换其他公司
3M的季度营收约是GLAUKOS Corp的42.1倍（$6.0B vs $143.1M）。3M净利率更高（10.8% vs -93.4%，领先104.2%）。GLAUKOS Corp同比增速更快（35.7% vs 1.3%）。3M自由现金流更多（$2.0B vs $3.9M）。过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs -1.8%）
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
3M是美国知名跨国综合企业，业务覆盖工业、劳动者安全防护、消费品等多个领域，总部位于圣保罗郊区的枫木市。公司现有超6万款产品，涵盖胶粘剂、研磨材料、防火防护产品、个人防护装备、窗膜、车漆保护膜、电子连接绝缘材料、汽车养护产品、光学膜等品类。
GKOS vs MMM — 直观对比
营收规模更大
MMM
是对方的42.1倍
$143.1M
营收增速更快
GKOS
高出34.4%
1.3%
净利率更高
MMM
高出104.2%
-93.4%
自由现金流更多
MMM
多$2.0B
$3.9M
两年增速更快
GKOS
近两年复合增速
-1.8%
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $143.1M | $6.0B |
| 净利润 | $-133.7M | $653.0M |
| 毛利率 | -1.1% | 40.7% |
| 营业利润率 | -97.7% | 23.2% |
| 净利率 | -93.4% | 10.8% |
| 营收同比 | 35.7% | 1.3% |
| 净利润同比 | -298.0% | -41.5% |
| 每股收益（稀释后） | $-2.34 | $1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GKOSMMM
| Q1 26 | — | $6.0B | ||
| Q4 25 | $143.1M | $6.1B | ||
| Q3 25 | $133.5M | $6.5B | ||
| Q2 25 | $124.1M | $6.3B | ||
| Q1 25 | $106.7M | $6.0B | ||
| Q4 24 | $105.5M | $6.0B | ||
| Q3 24 | $96.7M | $6.3B | ||
| Q2 24 | $95.7M | $6.3B |
净利润GKOSMMM
| Q1 26 | — | $653.0M | ||
| Q4 25 | $-133.7M | $577.0M | ||
| Q3 25 | $-16.2M | $834.0M | ||
| Q2 25 | $-19.7M | $723.0M | ||
| Q1 25 | $-18.1M | $1.1B | ||
| Q4 24 | $-33.6M | $728.0M | ||
| Q3 24 | $-21.4M | $1.4B | ||
| Q2 24 | $-50.5M | $1.1B |
毛利率GKOSMMM
| Q1 26 | — | 40.7% | ||
| Q4 25 | -1.1% | 33.6% | ||
| Q3 25 | 78.4% | 41.8% | ||
| Q2 25 | 78.3% | 42.5% | ||
| Q1 25 | 77.2% | 41.6% | ||
| Q4 24 | 72.9% | 51.7% | ||
| Q3 24 | 76.6% | 42.1% | ||
| Q2 24 | 76.4% | 42.9% |
营业利润率GKOSMMM
| Q1 26 | — | 23.2% | ||
| Q4 25 | -97.7% | 13.0% | ||
| Q3 25 | -12.3% | 22.2% | ||
| Q2 25 | -18.3% | 18.0% | ||
| Q1 25 | -19.4% | 20.9% | ||
| Q4 24 | -27.2% | 12.2% | ||
| Q3 24 | -25.5% | 20.9% | ||
| Q2 24 | -31.3% | 20.3% |
净利率GKOSMMM
| Q1 26 | — | 10.8% | ||
| Q4 25 | -93.4% | 9.4% | ||
| Q3 25 | -12.2% | 12.8% | ||
| Q2 25 | -15.8% | 11.4% | ||
| Q1 25 | -17.0% | 18.7% | ||
| Q4 24 | -31.8% | 12.1% | ||
| Q3 24 | -22.1% | 21.8% | ||
| Q2 24 | -52.8% | 18.3% |
每股收益（稀释后）GKOSMMM
| Q1 26 | — | $1.23 | ||
| Q4 25 | $-2.34 | $1.07 | ||
| Q3 25 | $-0.28 | $1.55 | ||
| Q2 25 | $-0.34 | $1.34 | ||
| Q1 25 | $-0.32 | $2.04 | ||
| Q4 24 | $-0.56 | $1.33 | ||
| Q3 24 | $-0.39 | $2.48 | ||
| Q2 24 | $-1.00 | $2.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.8M | $3.7B |
| 总债务越低越好 | — | $10.9B |
| 股东权益账面价值 | $656.2M | $3.3B |
| 总资产 | $893.5M | $35.4B |
| 负债/权益比越低杠杆越低 | — | 3.29× |
8季度趋势，按日历期对齐
现金及短期投资GKOSMMM
| Q1 26 | — | $3.7B | ||
| Q4 25 | $90.8M | — | ||
| Q3 25 | $98.2M | — | ||
| Q2 25 | $100.8M | — | ||
| Q1 25 | $114.3M | — | ||
| Q4 24 | $169.6M | — | ||
| Q3 24 | $100.1M | — | ||
| Q2 24 | $68.1M | — |
总债务GKOSMMM
| Q1 26 | — | $10.9B | ||
| Q4 25 | — | $12.6B | ||
| Q3 25 | — | $12.6B | ||
| Q2 25 | — | $13.1B | ||
| Q1 25 | — | $13.5B | ||
| Q4 24 | — | $13.0B | ||
| Q3 24 | — | $13.2B | ||
| Q2 24 | — | $13.1B |
股东权益GKOSMMM
| Q1 26 | — | $3.3B | ||
| Q4 25 | $656.2M | $4.7B | ||
| Q3 25 | $769.5M | $4.6B | ||
| Q2 25 | $765.1M | $4.3B | ||
| Q1 25 | $764.0M | $4.5B | ||
| Q4 24 | $766.9M | $3.8B | ||
| Q3 24 | $668.5M | $4.6B | ||
| Q2 24 | $665.2M | $3.9B |
总资产GKOSMMM
| Q1 26 | — | $35.4B | ||
| Q4 25 | $893.5M | $37.7B | ||
| Q3 25 | $999.4M | $37.6B | ||
| Q2 25 | $987.0M | $38.0B | ||
| Q1 25 | $966.2M | $40.0B | ||
| Q4 24 | $974.8M | $39.9B | ||
| Q3 24 | $926.5M | $40.9B | ||
| Q2 24 | $919.7M | $43.4B |
负债/权益比GKOSMMM
| Q1 26 | — | 3.29× | ||
| Q4 25 | — | 2.68× | ||
| Q3 25 | — | 2.72× | ||
| Q2 25 | — | 3.06× | ||
| Q1 25 | — | 3.02× | ||
| Q4 24 | — | 3.40× | ||
| Q3 24 | — | 2.84× | ||
| Q2 24 | — | 3.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.8M | — |
| 自由现金流经营现金流 - 资本支出 | $3.9M | $2.0B |
| 自由现金流率自由现金流/营收 | 2.7% | 33.6% |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-22.5M | $3.7B |
8季度趋势，按日历期对齐
经营现金流GKOSMMM
| Q1 26 | — | — | ||
| Q4 25 | $6.8M | $1.6B | ||
| Q3 25 | $-10.1M | $1.8B | ||
| Q2 25 | $7.0M | $-954.0M | ||
| Q1 25 | $-18.5M | $-79.0M | ||
| Q4 24 | $507.0K | $1.8B | ||
| Q3 24 | $-9.6M | $-1.8B | ||
| Q2 24 | $-18.4M | $1.0B |
自由现金流GKOSMMM
| Q1 26 | — | $2.0B | ||
| Q4 25 | $3.9M | $1.3B | ||
| Q3 25 | $-11.7M | $1.5B | ||
| Q2 25 | $5.8M | $-1.2B | ||
| Q1 25 | $-20.5M | $-315.0M | ||
| Q4 24 | $-1.2M | $1.5B | ||
| Q3 24 | $-11.0M | $-2.0B | ||
| Q2 24 | $-20.5M | $752.0M |
自由现金流率GKOSMMM
| Q1 26 | — | 33.6% | ||
| Q4 25 | 2.7% | 21.8% | ||
| Q3 25 | -8.8% | 23.6% | ||
| Q2 25 | 4.7% | -18.3% | ||
| Q1 25 | -19.2% | -5.3% | ||
| Q4 24 | -1.2% | 25.4% | ||
| Q3 24 | -11.4% | -32.3% | ||
| Q2 24 | -21.4% | 12.0% |
资本支出强度GKOSMMM
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 4.0% | ||
| Q3 25 | 1.2% | 3.3% | ||
| Q2 25 | 0.9% | 3.3% | ||
| Q1 25 | 1.8% | 4.0% | ||
| Q4 24 | 1.6% | 4.8% | ||
| Q3 24 | 1.5% | 3.9% | ||
| Q2 24 | 2.2% | 4.3% |
现金转化率GKOSMMM
| Q1 26 | — | — | ||
| Q4 25 | — | 2.74× | ||
| Q3 25 | — | 2.11× | ||
| Q2 25 | — | -1.32× | ||
| Q1 25 | — | -0.07× | ||
| Q4 24 | — | 2.50× | ||
| Q3 24 | — | -1.30× | ||
| Q2 24 | — | 0.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
MMM
| Safety and Industrial business segment | $2.9B | 49% |
| Transportation and Electronics business segment | $1.8B | 31% |
| Consumer business segment | $1.1B | 19% |
| Corporate | $121.0M | 2% |
